

Dietary and Circulating Fatty Acids and Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition



Sahar Yammine¹, Inge Huybrechts¹, Carine Biessy¹, Laure Dossus¹, Elom K. Aglago¹, Sabine Naudin¹, Pietro Ferrari¹, Elisabete Weiderpass¹, Anne Tjønneland^{2,3}, Louise Hansen², Kim Overvad⁴, Francesca R. Mancini^{5,6}, Marie-Christine Boutron-Ruault^{5,6}, Marina Kvaskoff^{5,6}, Renée T. Fortner⁷, Rudolf Kaaks⁷, Matthias B. Schulze^{8,9}, Heiner Boeing⁸, Antonia Trichopoulou¹⁰, Anna Karakatsani^{10,11}, Carlo La Vecchia^{10,12}, Vassiliki Benetou¹³, Giovanna Masala¹⁴, Vittorio Krogh¹⁵, Amalia Mattiello¹⁶, Alessandra Macciotta¹⁷, Inger T. Gram¹⁸, Guri Skeie¹⁸, Jose R. Quirós¹⁹, Antonio Agudo²⁰, Maria-José Sánchez^{21,22,23,24}, Maria-Dolores Chirlaque^{23,25}, Eva Ardanaz^{23,26,27}, Leire Gil²⁸, Hanna Sartor²⁹, Isabel Drake³⁰, Annika Idahl³¹, Eva Lundin³², Dagfinn Aune^{33,34,35}, Heather Ward³³, Melissa A. Merritt^{33,36}, Naomi E. Allen³⁷, Marc J. Gunter¹, and Véronique Chajès¹

ABSTRACT

Background: Fatty acids impact obesity, estrogens, and inflammation, which are risk factors for ovarian cancer. Few epidemiologic studies have investigated the association of fatty acids with ovarian cancer.

Methods: Within the European Prospective Investigation into Cancer and Nutrition (EPIC), 1,486 incident ovarian cancer cases were identified. Cox proportional hazard models with adjustment for ovarian cancer risk factors were used to estimate HRs of ovarian cancer across quintiles of intake of fatty acids. False discovery rate was computed to control for multiple testing. Multivariable conditional logistic regression models were used to estimate ORs of ovarian cancer across tertiles of plasma fatty acids among 633 cases and two matched controls in a nested case-control analysis.

Results: A positive association was found between ovarian cancer and intake of industrial *trans* elaidic acid [HR comparing fifth with first quintile_{Q5-Q1} = 1.29; 95% confidence interval (CI) = 1.03–1.62;

$P_{\text{trend}} = 0.02$, $q\text{-value} = 0.06$]. Dietary intakes of *n-6* linoleic acid (HR_{Q5-Q1} = 1.10; 95% CI = 1.01–1.21; $P_{\text{trend}} = 0.03$) and *n-3* α -linolenic acid (HR_{Q5-Q1} = 1.18; 95% CI = 1.05–1.34; $P_{\text{trend}} = 0.007$) from deep-frying fats were also positively associated with ovarian cancer. Suggestive associations were reported for circulating elaidic (OR comparing third with first tertile_{T3-T1} = 1.39; 95% CI = 0.99–1.94; $P_{\text{trend}} = 0.06$) and α -linolenic acids (OR_{T3-T1} = 1.30; 95% CI = 0.98–1.72; $P_{\text{trend}} = 0.06$).

Conclusions: Our results suggest that higher intakes and circulating levels of industrial *trans* elaidic acid, and higher intakes of linoleic acid and α -linolenic acid from deep-frying fat, may be associated with greater risk of ovarian cancer.

Impact: If causal, eliminating industrial *trans*-fatty acids could offer a straightforward public health action for reducing ovarian cancer risk.

¹International Agency for Research on Cancer, World Health Organization, Lyon, France. ²Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. ³Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁴Denmark Department of Public Health, Aarhus University, Aarhus, Denmark. ⁵CESP, Faculté de Médecine-Université Paris-Sud, Faculté de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. ⁶Gustave Roussy, Villejuif, France. ⁷The German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁸German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. ⁹Institute of Nutrition Science, University of Potsdam, Nuthetal, Germany. ¹⁰Hellenic Health Foundation, Athens, Greece. ¹¹2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece. ¹²Department of Clinical Sciences and Community Health Università degli Studi di Milano, Milan, Italy. ¹³Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. ¹⁴Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence, Italy. ¹⁵Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. ¹⁶Dipartimento di Medicina Clinica e Chirurgia, University of Naples Federico II, Naples, Italy. ¹⁷Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. ¹⁸Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. ¹⁹Public Health Directorate, Asturias, Spain. ²⁰Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology - ICO, Group of Research on Nutrition and Cancer, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. ²¹Andalusian School of Public Health (EASP), Granada, Spain. ²²Instituto de Investigación Biosanitaria de Granada (ibs. Granada),

Granada, Spain. ²³CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ²⁴Universidad de Granada, Granada, Spain. ²⁵Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain. ²⁶Navarra Public Health Institute, Pamplona, Spain. ²⁷IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. ²⁸Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, San Sebastian, Spain. ²⁹Diagnostic Radiology, Department of Translational Medicine, Lund University, Malmö, Sweden. ³⁰Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden. ³¹Department of Clinical Sciences, Obstetrics and Gynecology, Umeå, University, Umeå, Sweden. ³²Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden. ³³Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. ³⁴Department of Nutrition, Bjørknes University College, Oslo, Norway. ³⁵Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway. ³⁶University of Hawaii Cancer Center, Population Sciences in the Pacific Program, Honolulu, Hawaii. ³⁷Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Corresponding Author: Véronique Chajès, Nutrition and Metabolism, International Agency for Research on Cancer, World Health Organization, 150 cours Albert Thomas, 69373 Lyon cedex 08, France. Phone: 334-7273-8056; E-mail: chajesv@iarc.fr

Cancer Epidemiol Biomarkers Prev 2020;29:1739–49

doi: 10.1158/1055-9965.EPI-19-1477

©2020 American Association for Cancer Research.

Introduction

Ovarian cancer, with 295,414 new cases and 184,799 deaths in 2018 worldwide, is the eighth most common cancer and the eighth most common cause of cancer-related death in women (1). As the incidence of ovarian cancer is rising worldwide, prevention strategies are urgently needed; however, few preventable factors have been identified (2). Data mainly derived from case-control studies suggest that a typical Western diet, high in fats and meats and low in vegetables, might be associated with a higher risk of epithelial ovarian cancer (EOC; ref. 3).

A systematic meta-analysis by the World Cancer Research Funds concluded there was "limited" evidence for a link between saturated/animal fat and *trans*-fatty acids and EOC risk (4). Data from the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Netherlands Cohort Studies reported a greater risk of EOC associated with a higher intake of saturated fat (5). In the EPIC study only, higher intake of polyunsaturated fatty acids (PUFA) was associated with higher risk of EOC (6). Finally, higher fat intake from animal sources, but not from plant sources, was associated with a greater risk of EOC in the National Institutes of Health-American Association of Retired Persons (NIH-AARP) diet and health study (7).

The aim of this study was to prospectively investigate the association between individual fatty acids intake from various food sources as well as circulating biomarker levels and EOC risk in the EPIC study.

Materials and Methods

Study design

The EPIC study includes 521,330 participants recruited between 1992 and 2000 from 23 centers across 10 European countries (8). The study design, recruitment procedures, and data collection have been described previously (9). Briefly, dietary information as well as socio-demographic and lifestyle data were collected at enrollment from all participants by administration of country-specific questionnaires.

Baseline anthropometric measurements and peripheral blood samples were also collected. Procedures for sample collection, processing, and storage are described in detail elsewhere (10).

From a total of 333,224 women enrolled in the EPIC study, women were excluded from the current analysis if they did not complete a lifestyle or dietary questionnaire ($n = 3,243$), or were classified in the top or bottom 1% of energy intake to energy requirement ($n = 6,467$), leaving 323,514 eligible women.

Informed consent forms were provided by all participants. The study was conducted in accordance with the Declaration of Helsinki and was ethically approved by the internal review board of the International Agency for Research on Cancer (IARC) and from local ethics committees in each participating country.

Assessment of dietary fatty acids intake

To compile the EPIC Nutrient Database (ENDB) for the EPIC study, a highly standardized procedure was used, adopting nutrient values from ten national food composition databases of the respective EPIC countries (11, 12). ENDB was used to match the EPIC data with fatty acid isomers using the National Nutrient Database for Standard Reference of the United States (NNDSS; further referred to as USDA table; ref. 13). A follow-up validation of the EPIC food frequency questionnaire using two repeated dietary questionnaires and 12 consecutive monthly 24-hour dietary recalls showed that intakes of fats and other nutrient/food items reported at recruitment across countries were reliable over time (14). For example, the Spearman correlation

coefficients reported for different types of fat intakes ranged between 0.14 and 0.75 in men and 0.30 and 0.73 in women. In another validation study within the EPIC cohort, Spearman correlation coefficients between the intake of saturated, monounsaturated, and polyunsaturated fat estimated through a self-administered 20-item short questionnaire and the FFQ were 0.50, 0.43, and 0.29 ($P < 0.01$), respectively (15). In addition, the reliability of fatty acid composition measured in human blood phospholipid by gas chromatography was assessed between three independent measurements of blood fatty acids in the Nurses' Health Study (NHS; ref. 16). The correlation coefficients between three measures over a 2-year period were greater than 0.50 for most fatty acids, including *trans*-fatty acids (16). These findings suggested that a single determination of dietary estimates and circulating phospholipid fatty acids can be acceptable.

Quality control was tested through the comparison of the nutrients included in the extended EPIC database with nutritional biomarkers available in the nested case-control studies in EPIC (e.g., correlation between *trans*-fatty acids derived from the dietary questionnaires and the fatty acids extracted from plasma phospholipids was 0.53).

Ascertainment of ovarian cancer cases

Incident EOCs were identified through population-based cancer registries or active follow-up. EOCs were classified as ovarian, fallopian tube, and primary peritoneal cancers based on the third revision of the International Classification of Diseases for Oncology codes C56.9, C57.0, and C48, respectively.

Among 323,514 women enrolled in the EPIC study, 1,624 first-incident EOCs were identified after a mean follow-up of 8.2 years. Cases were censored if they were nonepithelial ($n = 76$), or tumors of borderline malignancy ($n = 62$), leaving 1,486 EOC cases for the current analysis. Cancer endpoint data is based on the latest round of follow-up received from the EPIC centers and centralized at IARC between 2014 and 2016. For each EPIC study center, closure dates of the study period were defined as the latest dates of complete and verified follow-up for both cancer incidence and vital status (dates varied between centers, between June 2008 and December 2013).

Nested case-control study and analysis of plasma phospholipid fatty acids

A total of 1,075 cases of first-incident invasive EOC were identified among women who had completed the dietary questionnaire and provided a baseline blood sample. Samples from Denmark were not included in this analysis, resulting in 633 cases. For each case, two controls were randomly selected from female cohort members who were alive, had blood samples available, had no bilateral ovariectomy and were cancer-free at diagnosis of the matched case, using a sampling protocol described previously (17). Controls were matched to cases on study center, age at blood donation (± 1 year), time of the day of blood collection, fasting status, menopausal status, menstrual cycle phase for premenopausal women, and current use of oral contraceptives or hormonal replacement therapy (HRT).

Analysis of plasma phospholipid fatty acids

The methodology used to determine plasma phospholipid concentrations of sixty fatty acids from short-chain saturated fatty acids (SFA) to long-chain PUFA, including 15 *trans*-fatty acid isomers from industrial processes and animal sources, has been described previously (18). Samples from cases and controls were processed in the same batch, and laboratory staff was blinded to case-control status and quality controls. The relative amount of each fatty acid was expressed as percentage of total fatty acids and as absolute amount ($\mu\text{mol/L}$).

Table 1. Characteristics of the study population.

EPIC-wide study <i>N</i> = 323,376	EOC cases <i>n</i> = 1,486	Noncases^a <i>n</i> = 321,890	Nested case-control study	EOC cases <i>n</i> = 633	Controls <i>n</i> = 1,248	<i>P</i> ^b
Anatomic subtypes, number, (%^c)						
Serous	79 (53.4)	—		341 (53.7)	—	—
Mucinous	91 (6.1)	—		37 (5.8)	—	—
Endometrioid	135 (9.1)	—		69 (10.8)	—	—
Clear cell	68 (4.6)	—		23 (3.6)	—	—
Follow-up characteristics, mean ± SD^c						
Age at recruitment, years	54.7 ± 8.2	50.6 ± 9.8		54.7 ± 8.8	54.6 ± 8.8	Matched
Age at diagnosis, years	62.9 ± 9.8	—		62.6 ± 9.3	—	—
Follow-up, years	8.2 ± 4.7	13.9 ± 3.8		7.9 ± 4.5	14.7 ± 2.6	<0.001
Anthropometry						
Mean ± SD^c						
Weight, kg	67.3 ± 12.2	65.6 ± 11.6		67.7 ± 11.7	66.6 ± 11.7	0.14
Height, cm	162.5 ± 6.6	162.3 ± 6.7		160.1 ± 6.9	160.1 ± 6.7	0.83
BMI, kg.m ⁻²	25.5 ± 4.5	24.9 ± 4.4		26.3 ± 4.6	25.9 ± 4.6	0.08
Obese (BMI ≥30 kg/m ²), % ^c	14.8	12.3		19.9	17.5	0.20
Reproductive and hormone factors						
Number of full-term pregnancies ^d	1.9 ± 1.2	1.9 ± 1.2		1.9 ± 1.3	2.1 ± 1.3	<0.01
Nulliparous, %	16.3	14.1		16.2	12.3	0.02
Ever use oral contraceptives, % ^c						<0.01
Never	53.1	40.7		58.8	50.9	
Ever	46.9	59.3		41.2	49.1	
Ever use hormone replacement therapy ^e , % ^c						0.84
Never	67.3	75.2		74.6	74.2	
Ever	32.7	24.8		25.4	25.8	
Ever breastfed ^d , % ^c						0.10
No	28.6	27.8		28.4	24.8	
Yes	71.4	72.2		71.6	75.2	
Ovariectomy, % ^c						<0.01
No	97.6	95.8		98.4	95.4	
Unilateral	2.4	4.2		1.6	4.6	
Menopausal status, % ^c						Matched
Premenopausal	20.8	36.0		25.7	24.9	
Postmenopausal	61.2	44.4		59.9	59.5	
Perimenopausal	17.9	19.6		14.4	15.5	
Age at menopause ^e	49.6 ± 4.7	48.9 ± 4.8		49.7 ± 4.5	49.1 ± 4.7	0.07
Socioeconomic status and lifestyle						
Total energy intake, kcal/day	1,959.1 ± 527.9	1,991.6 ± 545.4		2,002.1 ± 540.3	1,993.1 ± 514.4	0.73
Alcohol intake, % ^c						0.01
None	7.7	6.7		8.8	7.1	
<5 g/day	49.9	48.9		56.8	52.2	
5–<14.9 g/day	26.4	27.3		20.2	25.9	
15.0–<29.9 g/day	10.7	11.0		10.9	9.6	
≥29.9 g/day	5.4	6.1		3.4	5.3	
Education status, %						0.66
None and primary school	31.9	27.8		40.6	40.5	
Technical or professional and secondary school	43.0	45.3		35.4	36.8	
Higher education	18.9	23.0		17.1	16.9	
Physical activity status, % ^c						0.52
Inactive	12.0	13.1		8.4	7.1	
Moderately inactive	31.3	33.0		23.4	25.9	
Moderately active	47.2	44.2		56.9	55.2	
Active	9.5	9.7		11.2	11.8	

(Continued on the following page)

Yamine et al.

Table 1. Characteristics of the study population. (Cont'd)

EPIC-wide study N = 323,376	EOC cases n = 1,486	Noncases^a n = 321,890	Nested case- control study	EOC cases n = 633	Controls n = 1,248	P^b
Smoking status, % ^c						
Never	54.1	56.9		59.3	61.3	
Former	26.3	23.1		22.6	22.1	
Current	19.6	20.0		18.1	16.6	
Dietary intake, (g/day)						
Median (95% CI)^e						
Dairy products	295.5 (50.6–781.5)	277.9 (51.1–720.7)		297.8 (49.1–751.8)	301.2 (46.9–733.1)	0.73
Cereal and cereal products	176.1 (75.9–365.7)	187.4 (77.0–386.9)		181.6 (73.5–376.3)	183.8 (80.9–383.9)	0.58
Meat and meat products	80.9 (4.9–166.1)	83.1 (2.4–178.0)		83.5 (8.9–163.4)	87.5 (15.1–171.2)	0.28
Fat	22.8 (5.1–55.5)	22.1 (5.5–53.5)		25.6 (6.9–59.4)	25.4 (5.7–54.8)	0.25
Vegetable oils	2.9 (0.0–36.9)	3.8 (0.0–39.7)		5.9 (0.1–50.1)	5.9 (0.2–47.9)	0.70
Butter	0.2 (0.0–22.3)	0.4 (0.0–21.0)		0.4 (0.0–23.1)	0.5 (0.0–20.2)	0.50
Margarine	7.7 (0.0–40.4)	4.3 (0.0–35.9)		2.7 (0.0–32.7)	2.2 (0.0–29.3)	0.26
Deep-frying fat	0.0 (0.0–1.4)	0.0 (0.0–1.5)		0.0 (0.0–2.6)	0.0 (0.0–2.4)	0.52
Cakes and biscuits	29.6 (1.1–125.3)	29.7 (0.1–112.3)		33.3 (0.0–14.6)	31.3 (0.0–125.3)	0.12
Sugar and confectionaries	30.0 (3.6–98.4)	28.7 (2.4–97.2)		26.7 (2.0–86.7)	27.0 (2.3–87.6)	0.36
Condiments and sauces	15.2 (0.9–56.6)	15.4 (0.9–55.9)		12.3 (0.1–51.5)	13.0 (0.4–50.1)	0.41
Fatty acid intake^f (g/day or mg/day)						
Median (95% CI)^e						
SFA (g/day)	24.0 (11.8–46.3)	24.9 (11.7–48.3)		40.8 ± 1.7	40.9 ± 1.3	0.30
<i>cis</i> MUFA (g/day)	23.3 (11.6–45.6)	24.6 (12.1–48.1)		12.9 ± 2.1	12.9 ± 2.0	0.95
rTFA (mg/day)	23.4 (3.8–123.9)	28.2 (4.3–134.6)		0.4 ± 0.2	0.4 ± 0.2	0.34
iTFA (g/day)	1.4 (0.2–5.2)	1.2 (0.2–4.8)		0.7 ± 0.3	0.7 ± 0.4	0.94
<i>n</i> -6 PUFA (g/day)	11.5 (5.6–21.3)	11.4 (5.8–22.4)		37.6 ± 3.3	37.5 ± 3.3	0.44
Linoleic acid (g/day)	11.5 (5.6–21.3)	11.4 (5.7–22.3)		22.5 ± 3.4	22.4 ± 3.4	0.35
<i>n</i> -6 long-chain PUFA (mg/day)	23.5 (6.5–66.2)	24.2 (5.7–66.2)		15.0 ± 2.5	15.0 ± 2.5	0.78
<i>n</i> -3 PUFA (mg/day)	729.4 (258.7–2,066.4)	665.4 (237.7–1,907.2)		7.3 ± 2.3	7.3 ± 2.3	0.54
α -linolenic acid (mg/day)	421.2 (122.7–1,326.5)	383.1 (117.5–1,252.1)		0.2 ± 0.1	0.2 ± 0.1	0.47
<i>n</i> -3 long-chain PUFA (mg/day)	208.3 (24.5–1,129.2)	196.8 (21.9–1,037.9)		7.1 ± 2.1	7.1 ± 2.3	0.52
Phospholipid fatty acids^f (% of total fatty acids)						
Mean ± SD^c						
SFA				40.8 ± 1.7	40.9 ± 1.3	0.30
<i>cis</i> MUFA				12.9 ± 2.1	12.9 ± 2.0	0.95
rTFA				0.4 ± 0.2	0.4 ± 0.2	0.34
iTFA				0.7 ± 0.3	0.7 ± 0.4	0.94
<i>n</i> -6 PUFA				37.6 ± 3.3	37.5 ± 3.3	0.44
Linoleic acid				22.5 ± 3.4	22.4 ± 3.4	0.35
<i>n</i> -6 long-chain PUFA				15.0 ± 2.5	15.0 ± 2.5	0.78
<i>n</i> -3 PUFA				7.3 ± 2.3	7.3 ± 2.3	0.54
α -linolenic acid				0.2 ± 0.1	0.2 ± 0.1	0.47
<i>n</i> -3 long-chain PUFA				7.1 ± 2.1	7.1 ± 2.3	0.52

^aConsidered as noncases at the most recent cancer endpoint and vital status update.^bStudent *t* test for continuous variables and χ^2 test for categorical variables in the nested case-control approach.^cContinuous variables are presented as means ± SD or median (95% CI). Categorical variables are presented as percentages. Missing values were excluded from percentage calculations.^dAmong parous women.^eAmong postmenopausal women only.^fGroupings of fatty acids are as described in Materials and Methods.

The coefficients of variation (CV) were calculated using two quality control samples within each batch. Overall CV (intra- and inter-assays) ranged from 0.013% for large peaks (16:0) to 9.34% for the smallest peaks (18:3n-3ctt). All laboratory analyses were performed at IARC (Lyon, France).

Using values for 60 individual fatty acids, we calculated the percentage of the following groups: SFA, *cis* monounsaturated fatty acid (MUFA), ruminant *trans*-fatty acid (rTFA), industrial *trans*-fatty acid (iTFA), *cis n*-6 PUFA (18:2, 18:3, 20:2, 20:3, 20:4, 22:4, 22:5), and *cis n*-3 PUFA. We calculated the ratio of long-chain *n*-6/long-chain *n*-3 PUFA. We also determined the desaturation indexes DI₁₆ and DI₁₈ as biomarkers of endogenous lipogenesis of MUFA (19).

Statistical analyses

In the descriptive statistics for sociodemographic and lifestyle characteristics and dietary intake of fatty acids, frequencies were reported for the categorical variables and means ± SDs were calculated

for the continuous variables. HRs and 95% confidence intervals (CI) for the association between dietary fatty acids and EOC risk were calculated by Cox proportional hazards regression using age as the time metric; the entry time was age at recruitment and the exit time was age at cancer diagnosis, death, emigration, or last complete follow-up, whichever occurred first. Fatty acid intake among all cohort participants was stratified into quintiles, and the lowest category was set as the reference group. All models were stratified by the study center and age at enrollment. The retained multivariable model was adjusted for duration of oral contraceptive use (never use; use <5 years; use ≥5 years; missing), parity (number of live and/or stillborn children: 0; 1–2; 3–4; >4; missing), menopausal status at enrollment (premenopausal; postmenopausal; perimenopausal/unknown menopause), and total energy intake (continuous). Additional potential confounders [history/duration of breastfeeding, ever use of postmenopausal hormones, history of unilateral ovariectomy, body mass index (BMI), physical activity, tobacco smoking, education status, and intake of

Table 2. Association of estimated dietary intakes of fatty acids with ovarian cancer risk in the EPIC cohort.

	Q1 Reference	Q2	Q3	Q4	Q5	<i>P</i> _{trend} ^a	<i>q</i> _{trend} ^b
Total SFA^c							
Mean intake ± SD (g/d)	13.51 ± 2.80	19.90 ± 1.47	25.03 ± 1.54	31.15 ± 2.11	44.60 ± 9.13		
Cases/noncases (n)	329/64,342	303/64,368	326/64,344	269/64,402	259/64,411		
HR (95% CI) ^d	1.00	0.93 (0.79–1.10)	1.10 (0.92–1.32)	0.96 (0.78–1.18)	1.12 (0.87–1.44)	0.44	0.60
Palmitic acid (16:0)							
Mean intake ± SD (g/d)	7.51 ± 1.45	10.77 ± 0.74	13.30 ± 0.75	16.25 ± 0.99	22.48 ± 4.15		
Cases/noncases (n)	341/64,331	299/64,371	329/64,341	250/64,421	267/64,403		
HR (95% CI) ^d	1.00	0.92 (0.78–1.09)	1.08 (0.90–1.30)	0.89 (0.72–1.11)	1.13 (0.87–1.48)	0.63	0.78
Odd chain SFA^e							
Mean intake ± SD (mg/d)	50.00 ± 20.00	90.00 ± 10.00	140.00 ± 10.00	200.00 ± 20.00	340.00 ± 140.00		
Cases/noncases (n)	334/64,337	309/64,363	267/64,403	301/64,369	275/64,395		
HR (95% CI) ^d	1.00	1.03 (0.87–1.22)	0.93 (0.78–1.12)	1.07 (0.89–1.30)	1.12 (0.90–1.39)	0.31	0.49
Total <i>cis</i> MUFA^f							
Mean intake ± SD (g/d)	13.76 ± 2.63	19.77 ± 1.39	24.65 ± 1.47	30.64 ± 2.11	44.32 ± 9.44		
Cases/noncases (n)	346/64,325	326/64,345	295/64,375	285/64,386	234/64,436		
HR (95% CI) ^d	1.00	1.04 (0.89–1.24)	1.02 (0.85–1.24)	1.15 (0.92–1.43)	1.15 (0.86–1.53)	0.27	0.45
Oleic acid (18:1<i>n</i>-9)							
Mean intake ± SD (g/d)	12.72 ± 2.44	18.34 ± 1.32	23.02 ± 1.41	28.78 ± 2.01	42.04 ± 9.21		
Cases/noncases (n)	342/64,329	341/64,331	286/64,383	282/64,389	235/64,435		
HR (95% CI) ^d	1.00	1.14 (0.96–1.34)	1.02 (0.85–1.25)	1.18 (0.95–1.48)	1.19 (0.89–1.60)	0.25	0.45
Total rTFA^g							
Mean intake ± SD (mg/d)	6.00 ± 3.00	15.00 ± 3.00	29.00 ± 5.00	52.00 ± 8.00	120.00 ± 57.00		
Cases/noncases (n)	382/64,289	293/64,381	277/64,390	291/64,382	243/64,425		
HR (95% CI) ^d	1.00	0.96 (0.80–1.14)	0.94 (0.78–1.15)	1.03 (0.84–1.27)	1.01 (0.81–1.27)	0.67	0.78
Total iTFA^h							
Mean intake ± SD (g/d)	0.30 ± 0.14	0.74 ± 0.12	1.21 ± 0.15	1.93 ± 0.28	4.18 ± 1.67		
Cases/noncases (n)	234/64,437	255/64,416	286/64,384	323/64,348	388/64,282		
HR (95% CI) ^d	1.00	1.16 (0.95–1.41)	1.23 (0.99–1.51)	1.29 (1.04–1.60)	1.34 (1.06–1.67)	0.01	0.04
Elaidic acid (18:1<i>n</i>-9/12)							
Mean intake ± SD (g/d)	0.27 ± 0.13	0.69 ± 0.12	1.14 ± 0.15	1.85 ± 0.28	4.11 ± 1.67		
Cases/noncases (n)	238/64,433	254/64,417	280/64,390	323/64,348	391/64,279		
HR (95% CI) ^d	1.00	1.13 (0.93–1.37)	1.17 (0.95–1.44)	1.24 (1.01–1.54)	1.29 (1.03–1.62)	0.02	0.06
Total <i>cis</i> <i>n</i>-6 PUFAⁱ							
Mean intake ± SD (g/d)	6.51 ± 1.17	9.21 ± 0.63	11.42 ± 0.67	14.17 ± 0.97	20.69 ± 4.81		
Cases/noncases (n)	308/64,363	271/64,400	283/64,387	327/64,344	297/64,373		
HR (95% CI) ^d	1.00	0.99 (0.83–1.17)	1.13 (0.94–1.36)	1.32 (1.09–1.60)	1.33 (1.06–1.67)	0.001	0.005
Linoleic acid (18:2<i>n</i>-6)							
Mean intake ± SD (g/d)	6.48 ± 1.16	9.17 ± 0.63	11.38 ± 0.67	14.13 ± 0.97	20.64 ± 4.80		
Cases/noncases (n)	309/64,362	270/64,401	280/64,390	329/64,342	298/64,372		
HR (95% CI) ^d	1.00	0.99 (0.83–1.17)	1.11 (0.93–1.33)	1.37 (1.13–1.66)	1.34 (1.07–1.67)	<0.001	0.005
Total long-chain <i>n</i>-6 PUFA^l							
Mean intake ± SD (mg/d)	8.00 ± 3.00	17.00 ± 2.00	24.00 ± 2.00	34.00 ± 4.00	61.00 ± 24.00		
Cases/noncases (n)	287/64,384	337/64,348	278/64,384	288/64,377	296/64,374		
HR (95% CI) ^d	1.00	1.08 (0.91–1.29)	1.14 (0.95–1.37)	1.24 (1.01–1.51)	1.21 (0.97–1.50)	0.42	0.60
Total <i>cis</i> <i>n</i>-3 PUFA^k							
Mean intake ± SD (g/d)	0.29 ± 0.08	0.49 ± 0.05	0.67 ± 0.06	0.93 ± 0.10	1.70 ± 0.61		
Cases/noncases (n)	252/64,420	273/64,397	281/64,389	308/64,363	372/64,298		
HR (95% CI) ^d	1.00	1.09 (0.91–1.31)	1.12 (0.93–1.36)	1.12 (0.91–1.37)	1.15 (0.93–1.43)	0.25	0.45
α-linolenic acid (18:3<i>n</i>-3)							
Mean intake ± SD (g/d)	0.15 ± 0.05	0.27 ± 0.03	0.38 ± 0.04	0.56 ± 0.07	1.10 ± 0.44		
Cases/noncases (n)	260/64,411	262/64,409	278/64,393	306/64,364	380/64,290		
HR (95% CI) ^d	1.00	1.01 (0.84–1.21)	1.10 (0.92–1.33)	1.17 (0.97–1.42)	1.29 (1.05–1.58)	0.007	0.002
Total long-chain <i>n</i>-3 PUFA^l							
Mean intake (mg/d)	40.00 ± 21.00	110.00 ± 21.00	200.00 ± 27.00	340.00 ± 60.00	920.00 ± 604.00		
Cases/noncases (n)	273/64,398	293/64,378	276/64,395	300/64,370	344/64,326		
HR (95% CI) ^d	1.00	1.052 (0.86–1.22)	0.95 (0.78–1.14)	1.02 (0.84–1.24)	0.96 (0.78–1.19)	0.76	0.81
Total <i>cis</i> PUFA^m							
Mean intake ± SD (g/d)	7.05 ± 1.23	9.88 ± 0.66	12.20 ± 0.70	15.07 ± 1.01	21.87 ± 5.01		
Cases/noncases (n)	300/64,371	268/64,403	278/64,392	330/64,341	310/64,360		
HR (95% CI) ^d	1.00	0.99 (0.84–1.19)	1.12 (0.94–1.34)	1.39 (1.15–1.68)	1.41 (1.13–1.77)	<0.001	0.005

(Continued on the following page)

Table 2. Association of estimated dietary intakes of fatty acids with ovarian cancer risk in the EPIC cohort. (Cont'd)

	Q1 Reference	Q2	Q3	Q4	Q5	P_{trend}^a	q_{trend}^b
Ratio <i>n</i> -6/ <i>n</i> -3 PUFA							
Mean intake \pm SD	7.80 \pm 2.29	13.08 \pm 1.24	17.47 \pm 1.34	23.12 \pm 2.06	38.91 \pm 28.11		
Cases/noncases (<i>n</i>)	405/64,266	299/64,372	262/64,408	279/64,392	241/64,429		
HR (95% CI) ^d	1.00	0.87 (0.74–1.03)	0.90 (0.75–1.08)	1.03 (0.86–1.25)	0.92 (0.75–1.13)	0.99	0.99

^a*P* or *q* values < 0.05 are shown in boldface type.

^bValue for FDR correction.

^cTotal SFA included 4:0, 6:0, 8:0, 10:0, 12:0, 14:0, 15:0, 16:0, 17:0, 18:0, 20:0, 22:0, 24:0.

^dStratified by study center and age (in one-year categories), and adjusted for total duration of oral contraceptive use, parity, menopausal status, and total energy intake

^eOdd chain fatty acids included 15:0, 17:0.

^fTotal *cis* MUFA included 16:1*n*-7/*n*-9, 17:1, 18:1*n*-5, 18:1*n*-7, 18:1*n*-9, 20:1, 22:1, 24:1.

^gTotal rTFA included 18:1*n*-7t, CLA.

^hTotal iTFA included 16:1*n*-9t, 18:1*n*-9t, 18:2*n*-6tt, 18:3*n*-3ttt.

ⁱTotal *n*-6 PUFA included 18:2, 18:3, 20:2, 20:3, 20:4.

^jTotal long-chain *n*-6 PUFA included 20:2, 20:3, 20:4.

^kTotal *n*-3 PUFA included 18:3, 20:3, 20:5, 22:5, 22:6.

^lTotal long-chain *n*-3 PUFA included 20:3, 20:5, 22:5, 22:6.

^mTotal *cis*-PUFA included total *n*-6 PUFA and total *n*-3 PUFA.

alcohol, red meat, or total sugar] did not alter relative risks by 10% or more so were not included in the final models. A similar effect was observed for the mutual adjustment of fatty acids for one another. For each fatty acid, quintile-specific medians were used to compute the trend tests.

Q-values were calculated using the false discovery rate of the Benjamini–Hochberg procedure to correct for multiple testing (20).

In addition, the associations between dietary sources of individual fatty acids (as continuous variables) and EOC risk were investigated. The selected dietary sources were those that contributed to more than 1% of fatty acid intakes. The percentage of contribution was calculated for each food (sub-) group based on the mean daily intake reported in the questionnaire. The population proportion formula was used to determine the percentage contribution of each food group to the intake of each fatty acid component. This was done by summing the amount of the component provided by the food for all individuals divided by the total intake of that component from all foods for the entire study population.

The population attributable fraction (PAF) for fatty acids was estimated using the following equation, which uses the prevalence of fatty acid's exposure as categorical variable and the associated RR (or HR) in the current cancer cases:

$$\text{PAF} = \frac{\sum_{i=1}^k \text{RR}_i p_i - \sum_{i=1}^k \text{RR}_i p_i^*}{\sum_{i=1}^k \text{RR}_i p_i}$$

With RR_i and p_i expressing the adjusted HR and the observed proportion of participants in category *i*, and p_i^* the counterfactual proportion of participants (21). Given the low EOC prevalence and under the proportional hazards assumption, HRs were correct approximations of risk ratios (RR_i). Confidence intervals were calculated by bootstrap sampling (22).

Plasma phospholipid fatty acid values were log-transformed, and geometric means with 95% CI were reported. Fatty acid values were divided into tertiles based on the distribution among the controls, and conditional logistic regression was used to estimate the effect on EOC risk. Models were adjusted for the same confounders as those selected above for the analyses on dietary intakes.

Cox proportional hazards competing risk analysis (23) was used to estimate HR and 95% CI by menopausal status. Heterogeneity tests

were based on chi-square statistics, calculated as the deviations of logistic beta-coefficients observed in each of the subgroups relative to the overall beta-coefficient.

To limit bias due to reverse causation, sensitivity analyses excluding cases diagnosed during the first 2 years of follow-up were also conducted.

All statistical analyses were carried out using STATA 14.0 (Stata-Corp). *P* values below 0.05 were considered statistically significant.

Results

Compared with the noncases, the EOC cases were more likely to have a higher BMI, be nulliparous, be postmenopausal, have ever used HRT, and have a lower education and were less likely to have ever used oral contraceptives. In the nested case-control analysis, cases were more likely to be nulliparous, and were less likely to have ever used oral contraceptives (Table 1).

A positive association was found between EOC risk and intakes of iTFA (HR comparing 5th with 1st quintile_{Q5-Q1} = 1.34; 95% CI = 1.06–1.67, P_{trend} = 0.01, *q*-value = 0.04) mainly driven by elaidic acid (HR_{Q5-Q1} = 1.29; 95% CI = 1.03–1.62; P_{trend} = 0.02, *q*-value = 0.06). A positive association was also reported between EOC risk and intakes of total PUFA (HR_{Q5-Q1} = 1.41, 95% CI = 1.13–1.77; P_{trend} < 0.001, *q*-value = 0.005), mainly driven by linoleic acid (HR_{Q5-Q1} = 1.34, 95% CI = 1.07–1.67; P_{trend} < 0.001, *q*-value = 0.005), and α -linolenic acid (HR_{Q5-Q1} = 1.29; 95% CI = 1.05–1.58; P_{trend} = 0.007, *q*-value = 0.002; Table 2). PAF estimate indicated that 11.7% (95% CI, 1.9%–27.4%) of EOC risk can be attributed to *trans* elaidic acid.

A borderline positive trend was reported between EOC risk and plasma phospholipid elaidic acid (OR comparing third with first tertile_{T3-T1} = 1.39; 95% CI = 0.99–1.94; P_{trend} = 0.06) but not with plasma phospholipid iTFA despite the high correlation between the individual elaidic and the total iTFA (Spearman ρ = 0.88, P < 0.001). A borderline positive trend was also reported between EOC risk and plasma phospholipid α -linolenic acid (OR_{T3-T1} = 1.30; 95% CI = 0.98–1.72, P_{trend} = 0.06; Table 3).

The overall positive association between linoleic acid and EOC risk was mainly driven by the contribution of deep-frying fat

Table 3. Association of plasma phospholipid fatty acids with ovarian cancer risk in the EPIC cohort.

Plasma phospholipid fatty acids (% of total fatty acids)	Tertile 1 Reference	Tertile 2 OR (95% CI)	Tertile 3 OR (95% CI)	<i>P</i> _{trend} ^a
Total SFA ^b				
Mean ± SD	39.58 ± 1.27	40.91 ± 0.25	42.20 ± 0.94	
Cases/controls (<i>n</i>)	233/418	185/416	215/414	
OR (95% CI) ^c	1.00	0.82 (0.64–1.06)	0.93 (0.70–1.23)	0.57
Palmitic acid (16:0)				
Mean ± SD	24.08 ± 1.57	25.88 ± 0.42	27.90 ± 1.12	
Cases/controls (<i>n</i>)	222/419	224/418	187/411	
OR (95% CI) ^c	1.00	0.94 (0.73–1.21)	0.81 (0.59–1.09)	0.17
Total <i>cis</i> MUFA ^d				
Mean ± SD	10.84 ± 0.93	12.76 ± 0.44	15.16 ± 1.55	
Cases/controls (<i>n</i>)	214/418	207/416	212/414	
OR (95% CI) ^c	1.00	0.96 (0.75–1.23)	0.94 (0.72–1.22)	0.63
Oleic acid (18:1 <i>n</i> -9)				
Mean ± SD	8.44 ± 0.77	10.08 ± 0.39	12.33 ± 1.49	
Cases/controls (<i>n</i>)	218/417	187/415	228/416	
OR (95% CI) ^c	1.00	0.85 (0.66–1.09)	0.99 (0.76–1.30)	0.95
Total rTFA ^e				
Mean ± SD	0.26 ± 0.06	0.41 ± 0.04	0.62 ± 0.15	
Cases/controls (<i>n</i>)	233/456	173/389	227/403	
OR (95% CI) ^c	1.00	0.91 (0.67–1.22)	1.14 (0.81–1.61)	0.40
Total iTFA ^f				
Mean ± SD	0.44 ± 0.06	0.62 ± 0.05	0.98 ± 0.48	
Cases/controls (<i>n</i>)	214/447	199/387	220/414	
OR (95% CI) ^c	1.00	1.11 (0.83–1.48)	1.15 (0.82–1.64)	0.40
Elaidic acid (18:1 <i>n</i> -9/12)				
Mean ± SD	0.14 ± 0.03	0.24 ± 0.04	0.55 ± 0.19	
Cases/controls (<i>n</i>)	196/419	211/425	226/404	
OR (95% CI) ^c	1.00	1.12 (0.86–1.47)	1.39 (0.99–1.94)	0.06
Total <i>cis</i> <i>n</i> -6 PUFA ^g				
Mean ± SD	34.08 ± 2.39	37.74 ± 0.64	40.91 ± 1.66	
Cases/controls (<i>n</i>)	214/417	195/415	224/416	
OR (95% CI) ^c	1.00	0.93 (0.71–1.19)	1.08 (0.84–1.41)	0.49
Linoleic acid (18:2 <i>n</i> -6)				
Mean ± SD	18.72 ± 1.98	22.38 ± 0.79	26.10 ± 1.92	
Cases/controls (<i>n</i>)	197/418	218/414	218/416	
OR (95% CI) ^c	1.00	1.20 (0.93–1.54)	1.17 (0.90–1.52)	0.23
Long-chain <i>n</i> -6 PUFA ^h				
Mean ± SD	12.40 ± 1.61	15.05 ± 0.55	17.68 ± 1.43	
Cases/controls (<i>n</i>)	221/416	195/418	217/414	
OR (95% CI) ^c	1.00	0.83 (0.64–1.08)	0.98 (0.74–1.28)	0.85
Total <i>cis</i> <i>n</i> -3 PUFA ⁱ				
Mean ± SD	5.26 ± 0.68	6.98 ± 0.47	9.92 ± 2.19	
Cases/controls (<i>n</i>)	230/426	216/408	187/414	
OR (95% CI) ^c	1.00	0.91 (0.71–1.16)	0.78 (0.59–1.04)	0.09
α-linolenic acid (18:3 <i>n</i> -3ccc)				
Mean ± SD	0.12 ± 0.02	0.18 ± 0.02	0.28 ± 0.07	
Cases/controls (<i>n</i>)	226/473	169/365	238/410	
OR (95% CI) ^c	1.00	1.01 (0.76–1.32)	1.30 (0.98–1.72)	0.06
Long chain <i>n</i> -3 PUFA ^j				
Mean ± SD	5.06 ± 0.67	6.76 ± 0.48	9.71 ± 2.19	
Cases/controls (<i>n</i>)	222/417	223/415	188/416	
OR (95% CI) ^c	1.00	0.93 (0.73–1.20)	0.80 (0.61–1.06)	0.13
Total <i>cis</i> PUFA ^k				
Mean ± SD	42.35 ± 1.74	45.06 ± 0.53	47.38 ± 1.34	
Cases/controls (<i>n</i>)	218/416	208/416	207/416	
OR (95% CI) ^c	1.00	0.97 (0.75–1.26)	0.95 (0.73–1.24)	0.73
Ratio <i>n</i> -6/ <i>n</i> -3 PUFA				
Mean ± SD	3.69 ± 0.78	5.47 ± 0.44	7.78 ± 1.54	
Cases/controls (<i>n</i>)	195/418	216/414	222/416	
OR (95% CI) ^c	1.00	1.12 (0.87–1.45)	1.21 (0.91–1.60)	0.19

(Continued on the following page)

Yamine et al.

Table 3. Association of plasma phospholipid fatty acids with ovarian cancer risk in the EPIC cohort. (Cont'd)

Plasma phospholipid fatty acids (% of total fatty acids)	Tertile 1 Reference	Tertile 2 OR (95% CI)	Tertile 3 OR (95% CI)	<i>P</i> _{trend} ^a
DI ₁₆ (16:1 <i>n</i> -7/ <i>n</i> -9/16:0)				
Cases/controls (<i>n</i>)	399/793	180/378	52/77	
OR (95% CI) ^c	1.00	0.94 (0.74-1.19)	1.22 (0.18-1.84)	0.70
DI ₁₈ (18:1 <i>n</i> -9/18:0)				
Cases/controls (<i>n</i>)	214/421	216/432	203/395	
OR (95% CI) ^c	1.00	0.99 (0.77-1.28)	0.95 (0.72-1.25)	0.71


Abbreviation: DI, desaturation index.

^a*P* values < 0.05 are shown in boldface.^bTotal SFA included 12:0, 14:0, 15:0, 16:0, 17:0, 18:0, 20:0, 22:0, 24:0.^cCases and controls (1:2) are matched for study center, menopausal status, age, fasting status, and time of the day at blood collection, and adjusted for duration of oral contraceptive use, parity, menopausal status, and total energy intake.^dTotal *cis* MUFA included 14:1, 15:1, 16:1*n*-7/*n*-9, 17:1, 18:1*n*-5, 18:1*n*-7, 18:1*n*-9, 20:1, 22:1, 24:1.^eTotal *r*TFA included 18:1*n*-7*t*, CLA.^fTotal *i*TFA included 16:1*n*-7*t*/*n*-9*t*, 18:1*n*-12/*n*-9*t*, 18:2*n*-6*tt*, 18:2*n*-6*tc*, 18:3*n*-3*ttt*.^gTotal *n*-6 PUFA included 18:2, 18:3, 20:2, 20:3, 20:4, 22:4, 22:5.^hTotal long-chain *n*-6 PUFA included 20:2, 20:3, 20:4, 22:4, 22:5.ⁱTotal *n*-3 PUFA included 18:3, 18:4, 20:4, 20:5, 22:5, 22:6.^jTotal long-chain *n*-3 PUFA included 20:4, 20:5, 22:5, 22:6.^kTotal *cis* PUFA included total *n*-6 PUFA and total *n*-3 PUFA.

(HR_{Q5-Q1} = 1.10; 95% CI, 1.01-1.21; **Fig. 1**). In contrast, an inverse association was found between linoleic acid from vegetable oils and EOC risk (HR_{Q5-Q1} = 0.97; 95% CI = 0.95-0.99; **Fig. 1**). The overall positive association between α -linolenic acid and EOC risk was mainly driven by the contribution of deep-frying fat (HR_{Q5-Q1} = 1.18; 95%

CI = 1.05-1.34) and margarine (HR_{Q5-Q1} = 1.02; 95% CI = 1.01-1.04; **Fig. 2**).

Stratified analysis by menopausal status showed a positive association between palmitic acid and EOC risk restricted to premenopausal women (HR_{Q5-Q1} = 2.13; 95% CI = 1.22-3.71),

**Figure 1.**

Association between *n*-6 linoleic acid and EOC risk according to dietary sources. The percentage of contribution next to the food item was calculated for each food (sub-) group based on the mean daily intake reported in the dietary questionnaire. It represents the contribution of the correspondent food to the linoleic acid intake. The multivariable model was adjusted for duration of oral contraceptive use, parity, menopausal status at enrollment, and total energy intake.

Fatty Acids and Ovarian Cancer Risk in EPIC




Figure 2.

Association between *n*-3 α -linolenic acid and EOC risk according to dietary sources. The percentage of contribution next to the food item was calculated for each food (sub-) group based on the mean daily intake reported in the dietary questionnaire. It represents the contribution of the correspondent food to the α -linolenic acid intake. The multivariable model was adjusted for duration of oral contraceptive use, parity, menopausal status at enrollment, and total energy intake.

while no association was found in postmenopausal women ($P_{\text{heterogeneity}} = 0.04$). All $P_{\text{heterogeneity}} > 0.05$.

Discussion

To our knowledge, this is the first prospective analysis of the association between dietary and circulating individual fatty acids and the risk of EOC. We found evidence of a higher risk of EOC associated with higher dietary intakes of *trans* elaidic acid, linoleic acid, and α -linolenic acid. Suggestive positive associations were reported for plasma phospholipid *trans* elaidic acid and α -linolenic acid. These associations did not vary according to histologic subtypes of EOC.

iTFA consumption is associated with increased all-cause mortality (24) and the WHO encourages the elimination of these fatty acids from the diet (25). TFA may have decreased in processed foods, but their intake may still be high in certain countries or vulnerable groups in the population (26). In our study, dietary intake of elaidic acid, the main iTFA was significantly positively associated with EOC risk, and risk increased at dietary intakes of iTFA below dietary limits of 1% recommended by WHO. Similarly, in our subset analysis, we found a borderline significant positive association between plasma phospholipid *trans* elaidic acid and EOC risk but not with plasma phospholipid iTFA. One case-control study conducted in New England reported a significant association between higher intake of *trans* fat and greater risk of EOC (27). These data need further replication and clarification but suggest that iTFA from industrial processes, even at low intakes, might increase EOC development. In the current study, PAF estimate indicated that 11.7% (95% CI, 1.9%–27.4%) of EOC risk can be attributed to industrial *trans* elaidic acid. Assuming the estimated HR between elaidic acid and EOC risk is a good approximation of the

causal relative risk, a total of 173 cases (range, 28–407 cases) could have been avoided in the population study if elaidic acid was removed from diet. As already reported in the EPIC (6) and the NIH-AARP Diet and Health studies (7), we found a positive association between intake of total PUFA and EOC risk. In this analysis, available data on individual fatty acids indicated that this positive association is mainly driven by linoleic acid and α -linolenic acid, essential PUFA of the *n*-6 and *n*-3 families, respectively. In contrast, no association was reported between intakes of linoleic and α -linolenic acid and EOC risk in the NHS (28). These disparities between the NHS study and our study might be due to differences in the number of cases between the two studies (301 cases in the NHS vs. 1,486 in this study). The possibility that these differences might be due to different intakes of these fatty acids or different dietary contributors in the two populations is not known but deserve further consideration. Our results were further confirmed by a positive trend between plasma phospholipid levels of α -linolenic acid and EOC risk in our subset analysis of the EPIC study, but not with plasma linoleic acid. This might be due to a higher endogenous conversion of linoleic acid to long-chain *n*-6 PUFA compared with the limited conversion of α -linolenic acid to its longer chain derivatives (29).

In contrast to iTFA including elaidic acid which are derived from processed foods and deep-frying fat only, linoleic and α -linolenic acids have various food sources—vegetable, animal, and industrial—contributing to their daily intakes. However, we found divergent associations between linoleic and α -linolenic acids and EOC according to their dietary sources. The positive association between linoleic acid and EOC risk is only significantly driven by deep-frying fat, even if deep-frying fat is a minor contributor to linoleic acid (0.28%). Other positive trends with linoleic acid from fruit, nuts and seeds, eggs and egg products and total fat were reported, but not significant. In

Yammine et al.

contrast, an inverse association was found between linoleic acid from vegetable oils and EOC risk. Regarding α -linolenic acid, the positive association with EOC is mainly driven by deep-frying fat and margarine. Other positive trends with α -linoleic acid from cereal and cereal products, meat and meat products, fat, sugar and confectionaries, cakes and biscuits, and condiments and sauces were reported but are not significant.

These data might suggest that linoleic and α -linolenic acids may not exert a direct effect on EOC development, which might be rather associated to coexposure to other potentially carcinogenic compounds occurring in foods exposed to deep-frying fat, such as aldehydes, oxidized lipids, heterocyclic compounds, *trans*-fatty acids, polymers, sterol derivatives, acrylamide, and acrolein (30).

Our study has several strengths including its prospective design, and a very large number of incident EOC cases. In addition, having information from both dietary estimates and circulating fatty acids allowed the comparison of these independent approaches. In addition, we were able to separate *n*-6 and *n*-3 *cis* PUFA isomers as well as *trans*-fatty acid isomers from natural and industrial processes in both food composition table and plasma phospholipids. The major limitation of the study is the single collection of questionnaires and blood samples at baseline. Another limitation was that we did not have data for ovariectomy conducted during follow-up.

Conclusion

Our results suggest that higher dietary intakes and circulating levels of industrial *trans* laidic acid, along with higher intakes of linoleic acid and α -linolenic acid originating mainly from deep-frying fat, may be associated with greater risk of EOC. If causal, eliminating laidic acid through a regulation on industrial processes and limiting their use as deep-frying fat could potentially offer a relatively straightforward public health action for reducing EOC risk.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Disclaimer

Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

Authors' Contributions

Conception and design: E. Weiderpass, A. Tjønneland, K. Overvad, H. Boeing, M.-J. Sánchez, M.-D. Chirlaque, E. Ardanaz, M.J. Gunter, V. Chajès

Development of methodology: I. Huybrechts, P. Ferrari, A. Tjønneland, H. Boeing, M.-D. Chirlaque, E. Ardanaz, E. Lundin, V. Chajès

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E. Weiderpass, A. Tjønneland, K. Overvad, M.-C. Boutron-Ruault,

R.T. Fortner, R. Kaaks, M.B. Schulze, H. Boeing, A. Trichopoulou, A. Karakatsani, V. Benetou, G. Masala, V. Krogh, A. Mattiello, G. Skeie, J.R. Quirós, A. Agudo, M.-J. Sánchez, M.-D. Chirlaque, E. Ardanaz, A. Idahl, E. Lundin, M.J. Gunter, V. Chajès

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Yammine, I. Huybrechts, C. Biessy, S. Naudin, P. Ferrari, L. Hansen, M. Kvaskoff, R.T. Fortner, I.T. Gram, I.T. Gram, E. Ardanaz, M.J. Gunter, V. Chajès

Writing, review, and/or revision of the manuscript: S. Yammine, I. Huybrechts, C. Biessy, L. Dossus, E.K. Aglago, S. Naudin, E. Weiderpass, A. Tjønneland, L. Hansen, K. Overvad, F.R. Mancini, M.-C. Boutron-Ruault, M. Kvaskoff, R.T. Fortner, M.B. Schulze, H. Boeing, A. Trichopoulou, A. Karakatsani, C.L. Vecchia, V. Benetou, G. Masala, V. Krogh, A. Mattiello, A. Macciotta, I.T. Gram, G. Skeie, J.R. Quirós, A. Agudo, M.-J. Sánchez, M.-D. Chirlaque, E. Ardanaz, L. Gil, H. Sartor, I. Drake, A. Idahl, E. Lundin, D. Aune, H. Ward, M.A. Merritt, N.E. Allen, M.J. Gunter, V. Chajès

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): I. Huybrechts, C. Biessy, R. Kaaks, A. Karakatsani, G. Skeie, J.R. Quirós, E. Ardanaz, V. Chajès

Study supervision: G. Skeie, A. Agudo, M.-D. Chirlaque, E. Ardanaz, M.J. Gunter, V. Chajès

Acknowledgments

The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM; France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); UiT The Arctic University of Norway; Health Research Fund (FIS, PI13/00061 to Granada), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Scientific Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; United Kingdom). This study was supported by the Institut National du Cancer (INCA; 2016-129). S. Yammine has been awarded a grant by the INCA (2016-184). The authors gratefully acknowledge Mrs. Béatrice Vozar and Mrs. Siham El Manssoury within the Lipidomic Platform at the International Agency for Research on Cancer, for their outstanding assistance with laboratory measurements of plasma fatty acids. The authors thank the participants of the EPIC study for their valuable contributions. The authors thank the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution and ongoing support to the EPIC study.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 26, 2019; revised March 3, 2020; accepted June 1, 2020; published first July 2, 2020.

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
- Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. *Lancet* 2002;360.
- Schulze M, Lahmann PH, Riboli E, Boeing H. Dietary determinants of epithelial ovarian cancer: a review of the epidemiologic literature. *Nutr Cancer* 2004;50:120-40.
- World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, nutrition, physical activity, and the prevention of ovarian cancer. London; Arlington (VA): WCRF; AICR; 2014.

Available from: <https://www.wcrf.org/sites/default/files/Ovarian-Cancer-2014-Report.pdf>.

- Merritt MA, Tzoulaki I, van den Brandt PA, Schouten LJ, Tsilidis KK, Weiderpass E, et al. Nutrient-wide association study of 57 foods/nutrients and epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study. *Am J Clin Nutr* 2016;103:161-7.
- Merritt MA, Riboli E, Weiderpass E, Tsilidis KK, Overvad K, Tjønneland A, et al. Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol* 2014;38:528-37.

Fatty Acids and Ovarian Cancer Risk in EPIC

7. Blank MM, Wentzensen N, Murphy MA, Hollenbeck A, Park Y. Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study. *Br J Cancer* 2012;106:596–602.
8. Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutrition. *Nat Rev Cancer* 2004;4:206–15.
9. Riboli E, Kaaks R. The EPIC Project: rationale and study design. *European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol* 1997;26 Suppl 1:S6–14.
10. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5:1113–24.
11. Slimani N, Deharveng G, Unwin I, Southgate DA, Vignat J, Skeie G, et al. The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. *Eur J Clin Nutr* 2007;61:1037–56.
12. Nicolas G, Witthöft CM, Vignat J, Knaze V, Hybrechts I, Roe M, et al. Compilation of a standardised international folate database for EPIC. *Food Chem* 2016;193:134–40.
13. U.S. Department of Agriculture, Agricultural Research Service, USDA Nutrient Data Laboratory. Composition of foods raw, processed, prepared. USDA National Nutrient Database for Standard Reference, Release 20. Bethesda (MD): U.S. Department of Agriculture; 2007. Available from: https://www.ars.usda.gov/ARSUserFiles/80400535/DATA/sr20/sr20_doc.pdf.
14. Kaaks R, Slimani N, Riboli E. Pilot phase studies on the accuracy of dietary intake measurements in the EPIC project: overall evaluation of results. *European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol* 1997;26 Suppl1: S26–36.
15. Rohrmann S, Klein G. Validation of a short questionnaire to qualitatively assess the intake of total fat, saturated, monounsaturated, polyunsaturated fatty acids, and cholesterol. *J Hum Nutr Diet* 2003;16:111–7.
16. Zeleniuch-Jacquotte A, Chajes V, Van Kappel AL, Riboli E, Toniolo P. Reliability of fatty acid composition in human serum phospholipids. *Eur J Clin Nutr* 2000; 54:367–72.
17. Terry KL, Schock H, Fortner RT, Hüsing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. *Clin Cancer Res* 2016;22:4664–75.
18. Chajes V, Assi N, Biessy C, Ferrari P, Rinaldi S, Slimani N, et al. A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. *Ann Oncol* 2017;28:2836–42.
19. Chajes V, Joulin V, Clavel-Chapelon F. The fatty acid desaturation index of blood lipids, as a biomarker of hepatic stearoyl-CoA desaturase expression, is a predictive factor of breast cancer risk. *Curr Opin Lipidol* 2011;22:6–10.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Roy Stat Soc Ser B* 1995;57: 289–300.
21. Barendregt JJ, Veerman JL. Categorical versus continuous risk factors and the calculation of potential impact fractions. *J Epidemiol Community Health* 2010; 64:209–12.
22. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. *Statist Sci* 1986;1:54–75.
23. Glynn RJ, Rosner B. Methods to evaluate risks for composite end points and their individual components. *J Clin Epidemiol* 2004;57:113–22.
24. de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. *BMJ* 2015;351:h3978.
25. Ghebreyesus TA, Frieden TR. REPLACE: a roadmap to make the world trans fat free by 2023. *Lancet* 2018;391:1978–80.
26. Stender S, Astrup A, Dyerberg J. Tracing artificial trans fat in popular foods in Europe: a market basket investigation. *BMJ Open* 2014;4:e005218.
27. Merritt MA, Cramer DW, Missmer SA, Vitonis AF, Titus LJ, Terry KL. Dietary fat intake and risk of epithelial ovarian cancer by tumour histology. *Br J Cancer* 2014;110:1392–401.
28. Bertone ER, Rosner BA, Hunter DJ, Stampfer MJ, Speizer FE, Colditz GA, et al. Dietary fat intake and ovarian cancer in a cohort of US women. *Am J Epidemiol* 2002;156:22–31.
29. Calder PC. Functional roles of fatty acids and their effects on human health. *J Parenter Enteral Nutr* 2015;39:18S–32S.
30. Zhang Q, Saleh AS, Chen J, Shen Q. Chemical alterations taken place during deep-fat frying based on certain reaction products: a review. *Chem Phys Lipids* 2012;165:662–81.

Cancer Epidemiology, Biomarkers & Prevention

Dietary and Circulating Fatty Acids and Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition

Sahar Yammine, Inge Huybrechts, Carine Biessy, et al.

Cancer Epidemiol Biomarkers Prev 2020;29:1739-1749. Published OnlineFirst July 2, 2020.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-19-1477](https://doi.org/10.1158/1055-9965.EPI-19-1477)

Cited articles This article cites 27 articles, 5 of which you can access for free at:
<http://cebp.aacrjournals.org/content/29/9/1739.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/29/9/1739>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.